AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03899064
Drug: Induction: Application of MC2-01 Cream, no irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Trial: NCT03899064
Drug: Induction: Applications of MC2-01 vehicle, irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Trial: NCT03899064
Drug: Induction: Applications of MC2-01 vehicle, no irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Trial: NCT03899064
Drug: Challenge: Application of MC2-01 Cream, irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Trial: NCT03899064
Drug: Challenge: Application of MC2-01 Cream, no irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Trial: NCT03899064
Drug: Challenge: Applications of MC2-01 vehicle, irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Trial: NCT03899064
Drug: Challenge: Applications of MC2-01 vehicle, no irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Trial: NCT03899064
Drug: Challenge: Control, irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
Trial: NCT00650455
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 10 mg tablet once daily for 12 weeks
Trial: NCT00650455
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg capsule twice daily for 12 weeks
Trial: NCT00650455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet every morning and capsule every evening for 12 weeks
Trial: NCT03952715
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
Trial: NCT03952715
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
Trial: NCT01454349
Drug: PRX302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
Trial: NCT01454349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraprostatic injection of matching placebo
Trial: NCT00628589
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo
Trial: NCT02253823
Drug: TPV/RTV - low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253823
Drug: TPV/RTV - high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02418312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus thienopyridine
Trial: NCT02303782
Drug: OTX015
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03542916
Drug: CJ-40001 60ug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CJ-40001 60ug SC, IV injection
Trial: NCT03542916
Drug: NESP 60ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NESP 60ug SC, IV injection
Trial: NCT01307202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match the the gabapentin pill and will be given orally.
Trial: NCT03483870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of normal saline 0.9% IV injection
Trial: NCT00289198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo nasal spray
Trial: NCT01960088
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01414764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively
Trial: NCT03421743
Drug: Antimycobacterial regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug NTM guideline-based antimycobacterial regimen
Trial: NCT00431951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules to match experimental drug
Trial: NCT01293643
Drug: 100 mg clindamycin /800 mg ketoconazole vaginal ovule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal ovule for 3 consecutive days
Trial: NCT01293643
Drug: 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 applicator (4 g) full of cream intravaginally for 7 to 10 days
Trial: NCT01296074
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
Trial: NCT03900923
Drug: 98% pure CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
Trial: NCT01939132
Drug: Open label H.P. Acthar Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
Trial: NCT01009346
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001
Trial: NCT00424411
Drug: Inhaled human insulin (EXUBERA™)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01532544
Drug: low molecular weight heparin.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00174538
Drug: Codeine (30 mg)
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00693472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule administered orally every 12 hours
Trial: NCT00693472
Drug: Anticholinergic agents or propanolol
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.
Trial: NCT02768714
Drug: Neulastim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
Trial: NCT01790555
Drug: Namisol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00690170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
Trial: NCT04375397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
Trial: NCT01304329
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium dose oral administration
Trial: NCT02973191
Drug: JCAR015
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01797380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for duration of double-blind portion of trial
Trial: NCT03508323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T/qd
Trial: NCT05052437
Drug: Utidelone Injection; capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
Trial: NCT03561701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule
Trial: NCT03542435
Drug: SXC-2023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT03542435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05551624
Drug: Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
Trial: NCT02784015
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02784015
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00624780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01152515
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
Trial: NCT01169584
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
Trial: NCT01825902
Drug: fluorine F 18 fluorothymidine
RxNorm normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo 18F-FLT PET
Trial: NCT03476616
Drug: Eplerenone (-based therapy) arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
Trial: NCT04407065
Drug: Double trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Trial: NCT04407065
Drug: HCG trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Trial: NCT04015869
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02474537
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 200 mg dose INC280
Trial: NCT01812369
Drug: METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02501564
Drug: Naproxen Sodium Codeine
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet twice a day
Trial: NCT02501564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice a day
Trial: NCT00837876
Drug: Erlotinb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg taken by mouth 1 time per day.
Trial: NCT03077555
Drug: Meliane ED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
Trial: NCT03558074
Drug: ALK4290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALK4290 400 mg tablet twice a day
Trial: NCT01116427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
Trial: NCT00461305
Drug: DRSP 3 mg/EE 20 µg (13 cycles)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
Trial: NCT00461305
Drug: DRSP 3 mg/EE 30 µg (6 cycles)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
Trial: NCT03609619
Drug: AEVI-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
Trial: NCT03609619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of Placebo will be administered twice daily, during the treatment period.
Trial: NCT04900948
Drug: cream 0.1% methylprednisolone aceponate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
Trial: NCT00657384
Drug: Nacl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
Trial: NCT02177409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02639338
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Trial: NCT02639338
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Trial: NCT02911688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
Trial: NCT00809328
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
Trial: NCT01634529
Drug: V158866
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending oral doses of V158866 and Placebo
Trial: NCT01634529
Drug: V158866
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending oral doses of V158866 and Placebo
Trial: NCT03825692
Drug: Zhizhu Kuanzhong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Trial: NCT03825692
Drug: Zhizhu Kuanzhong Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Trial: NCT00849602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid for three days
Trial: NCT01172756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT02482857
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare BID dosing with OD dosing with clinically used aspirin dosages.
Trial: NCT02310048
Drug: MT-1303-FormA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02630368
Drug: Cyclophosphamide and JX-594 dose escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Trial: NCT02630368
Drug: Cyclophosphamide and JX-594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Trial: NCT02630368
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
Trial: NCT02630368
Drug: Avelumab and JX-594 and Cyclophosphamide
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .
Trial: NCT04493684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally during each dosing day.
Trial: NCT04493684
Drug: GSK3739937 (Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3739937 Tablet will be administered via oral route.
Trial: NCT03449433
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03781791
Drug: Placebo Treatment
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in tablet form, once daily.
Trial: NCT02449018
Drug: QBW251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBW251 capsule(s) taken orally twice per day
Trial: NCT02449018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule(s) taken orally twice per day
Trial: NCT00806442
Drug: Borage Seed Oil and Echium Seed Oil
RxNorm normalized name: Echium plantagineum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
Trial: NCT04412694
Drug: Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative oral dexamathasone supplementation in a single dose of 8mg.
Trial: NCT04412694
Drug: Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative oral supplementation of sweetener in a single dose.